Topical Nifedipine: A Hyalurosomal Gel Deep Dive

Topical nifedipine has always been capped by how little drug gets across the cornea, and a hyalurosomal gel formulation puts numbers on how much that ceiling can move. Optimized vesicles came out at 198.6 nm carrying 70.7 percent entrapment, penetration depth doubled to 110 micrometers, and peak intraocular pressure reduction hit 51.85 percent against 36.4 percent for a commercial comparator.

Why topical nifedipine is an awkward molecule to deliver to the eye

Nifedipine is a dihydropyridine calcium channel blocker. The ocular logic is easy to follow: block calcium entry and vascular smooth muscle relaxes, which improves ocular blood flow, and lower intraocular pressure means less pressure driven loss of retinal ganglion cells.

Getting it into the eye is the problem. Nifedipine dissolves badly in water, degrades in light, and faces a cornea built as a lipophilic epithelium over a hydrophilic stroma. A molecule tuned to cross one layer usually handles the next one poorly. Add nasolacrimal drainage and a conventional drop has a residence time measured in minutes.

Glaucoma also is not one disease with one target. Pressure is one axis, oxidative stress driven neuronal loss is another, which is why pairing a pressure lowering agent with a neuroprotective one is good design rather than decoration.

What the formulation actually is

Vesicles were built by thin film hydration and optimized with a D-Optimal design screening particle size, polydispersity index, entrapment efficiency and zeta potential. These are hyalurosomes, meaning a phospholipid bilayer combined with hyaluronic acid, picked for its water binding, viscosity and mucoadhesive behavior.

Bile salts, sodium cholate and sodium deoxycholate, sat in the design space as edge activators. They make the bilayer more flexible, which is what lets a vesicle deform and squeeze through the corneal epithelium instead of bouncing off it.

The optimized vesicles were probe sonicated, combined with citicoline sodium, and loaded into a hydroxypropyl methylcellulose hydrogel. Three parts, then: a deformable vesicle, a gel that keeps it on the eye, and a second active working through a different mechanism.

Particle size, entrapment and surface charge

AttributeBefore sonicationAfter sonicationWhy it matters
Particle sizeLarger, broader distribution198.6 plus or minus 23.1 nmSmall enough to approach the epithelium closely
Polydispersity indexHigher0.4 plus or minus 0.1Acceptable spread for a vesicular system
Entrapment efficiencyNot reduced below useful levels70.7 plus or minus 1.8 percentEnough drug carried to make dosing practical
Zeta potential-40.9 plus or minus 1.4 mV-39.1 plus or minus 1.3 mVStill enough repulsion to stay physically stable

The sonication step deserves attention because it usually costs you something. Breaking vesicles down tends to dump the payload, and here entrapment held at 70.7 percent while size came down into the 200 nm range and surface charge barely moved, from -40.9 to -39.1 mV. Electron microscopy confirmed spherical, non aggregated vesicles with intact structure.

Rheology, pH and 24 hour release

The finished gel showed pseudoplastic shear thinning. That is exactly the behavior you want in a drop: thick enough to stay where it lands, thin enough under a blink to spread instead of dragging.

pH measured 6.9 plus or minus 0.02, inside the comfortable ocular range, which explains part of the tolerability picture later.

Release over 24 hours was 65.5 percent for nifedipine and 99.5 percent for citicoline sodium. Two rates out of one vehicle is not a defect, it is the design: slow release for the pressure lowering agent so effect is sustained, fast and complete release for the neuroprotectant.

Antioxidant activity: the combination beats either drug alone

Scavenging was measured by DPPH assay and expressed as the half maximal inhibitory concentration. The dual gel hit 16.44 plus or minus 0.7 micrograms per milliliter. Free nifedipine sat at 219.43 and free citicoline sodium at 234.62 micrograms per milliliter.

Roughly thirteen fold better than either drug alone. Nothing mysterious about the mechanism either: the vesicle puts both agents into the same lipid environment where the radical chemistry is happening, so local concentration ends up far above what either compound reaches in plain solution.

Corneal penetration: 2.2 fold deeper

Confocal microscopy tracked how far a fluorescent marker got into the cornea. Control solution stopped at 50 micrometers. The optimized gel reached 110 micrometers, 2.2 times deeper.

This is the number that carries the paper, because penetration is the constraint that has always capped topical nifedipine. Doubling depth into the cornea is what turns a molecule with good pharmacology into one with usable ocular exposure.

In vivo pressure lowering against a commercial comparator

Pharmacodynamic variableOptimized gelCommercial comparator drop
Maximum intraocular pressure decrease51.85 plus or minus 8.2 percent36.4 plus or minus 5.9 percent
Mean residence time8.9 plus or minus 2.7 hoursNot reported for the same variable
Relative exposure, AUC zero to infinity494.1 plus or minus 191.9182.8 plus or minus 33.7

About 15 percentage points separate the two on peak pressure reduction, and the exposure gap is wider still at roughly 2.7 fold on area under the curve. Both point the same direction: the gel is not only lowering pressure further, it is holding the effect longer, which the 8.9 hour residence time supports.

Animals were male adult albino rabbits under standard laboratory animal care guidance, run as a crossover with the pharmacokinetic variables computed in dedicated software.

Terminal sterilization by gamma irradiation

The gel was terminally sterilized by gamma irradiation from a cobalt 60 source at 25 kGy, and physicochemical characteriztics plus release profiles survived intact.

That is worth more than it looks. Plenty of vesicular systems do not survive terminal sterilization, because irradiation can cleave phospholipids, crosslink the polymer or shift the size distribution. A product that must be assembled aseptically is much harder to run at scale than one sterilized in its final container.

Ocular tolerability

Irritancy was assessed by Draize test and by histopathology. Both indicated excellent ocular tolerability with no irritation signals reported.

Bear in mind the formulation contains bile salt edge activators, which are surfactants and will irritate the ocular surface above some concentration. The result suggests the edge activator level needed for deformability sits below the level that damages tissue.

What this does and does not establish

What it establishes is formulation performance. The vesicle system is characterized properly, penetration is measured instead of assumed, and the pharmacodynamic comparison is against a marketed product rather than against nothing.

What it does not establish is clinical benefit. This is preclinical work in rabbits with intraocular pressure as the endpoint, and glaucoma decisions rest on visual field preservation over years. Nothing here speaks to that. The 51.85 percent pressure reduction is a pharmacodynamic result in an animal eye, not a patient outcome.

Nor is there stability data past the sterilization step, any scalability assessment, or a comparison against current first line glaucoma therapy.

Bottom line

Topical nifedipine performs better from a hyalurosomal gel than from solution, and the gain shows up at every level: 198.6 nm vesicles with 70.7 percent entrapment, 2.2 fold deeper corneal penetration, and a 51.85 percent peak pressure drop against 36.4 percent for a marketed comparator. Well executed formulation work with a clean preclinical signal and no clinical data yet.

FAQ

Why is nifedipine being studied for glaucoma

Nifedipine is a dihydropyridine calcium channel blocker that relaxes vascular smooth muscle, improving ocular blood flow and lowering intraocular pressure. Glaucoma damages retinal ganglion cells through pressure and through oxidative stress, so a molecule that addresses perfusion and pressure is a rational candidate if it can be delivered.

What stops topical nifedipine from working as a simple solution

Three things. The drug is poorly soluble in water and unstable in light, the cornea presents a lipophilic epithelium over a hydrophilic stroma, and nasolacrimal drainage clears a conventional drop within minutes. Penetration depth, not pharmacology, has always been the limiting factor. Each barrier has to be solved separately.

What is a hyalurosomal gel

Hyalurosomes are vesicles combining a phospholipid bilayer with hyaluronic acid, chosen for water binding, viscosity and mucoadhesive behavior. In this work they were prepared by thin film hydration, optimized by a D-Optimal design, then dispersed in a hydroxypropyl methylcellulose hydrogel. The hydrogel is what holds the vesicles on the ocular surface.

What particle size and entrapment efficiency were achieved

After probe sonication the optimized vesicles measured 198.6 plus or minus 23.1 nm with a polydispersity index of 0.4 plus or minus 0.1, and entrapment efficiency of 70.7 plus or minus 1.8 percent. Zeta potential moved only from -40.9 to -39.1 mV, so physical stability was retained. Sonication usually costs payload, and here it did not.

How much deeper did the gel penetrate the cornea

Confocal microscopy measured penetration depth of 110 micrometers for the optimized gel against 50 micrometers for a control solution, a 2.2 fold increase. Penetration is the barrier that has historically limited topical nifedipine, so this is the decisive measurement in the study. Depth was measured by confocal microscopy on excised corneal tissue.

How much did intraocular pressure fall in animal testing

Maximum intraocular pressure decrease was 51.85 plus or minus 8.2 percent for the optimized gel, against 36.4 plus or minus 5.9 percent for a commercially available comparator eye drop. Relative exposure measured as AUC zero to infinity was 494.1 against 182.8, roughly 2.7 fold higher. Both differences favor the gel on magnitude and on duration.

Why pair nifedipine with citicoline sodium

Glaucoma has two axes, pressure driven damage and oxidative stress driven neuronal loss. Citicoline sodium is a neuroprotective and antioxidant agent, so pairing it with a pressure lowering calcium channel blocker addresses both. The combination also showed far better radical scavenging than either drug alone.

What was the antioxidant result

Scavenging was measured by DPPH assay as a half maximal inhibitory concentration. The dual gel reached 16.44 plus or minus 0.7 micrograms per milliliter against 219.43 for free nifedipine and 234.62 for citicoline sodium, roughly a thirteen fold improvement over either compound in solution. Shared delivery into the same lipid environment is what produces it.

How long does the gel stay on the eye

Mean residence time was 8.9 plus or minus 2.7 hours, and the gel showed pseudoplastic shear thinning flow, meaning it is viscous between blinks and spreads under the shear of a blink. Release over 24 hours was 65.5 percent for nifedipine and 99.5 percent for citicoline. Viscosity between blinks is what extends contact time.

Can the formulation be sterilized in its final container

Yes. Terminal sterilization by gamma irradiation from a cobalt 60 source at 25 kGy preserved physicochemical characteriztics and release profiles. That matters because irradiation can cleave phospholipids or shift particle size, and aseptic assembly is far harder to run at scale. Surviving that dose is a manufacturability result, not a detail.

Was the gel irritating to the eye

No. The Draize test and histopathological examination both indicated excellent ocular tolerability. This is a meaningful result because the formulation contains bile salt edge activators, which are surfactants and can irritate the ocular surface at higher concentrations. No irritation signals were reported in either assessment.

Does this mean nifedipine gel is ready for glaucoma patients

No. This is preclinical work in rabbits with intraocular pressure as the endpoint, and glaucoma treatment decisions rest on visual field preservation over years. There is no clinical data, no long term stability data, and no comparison against current first line glaucoma therapy. Formulation performance and clinical benefit are not the same claim.

Comments are closed